Re: New waist size cutoff: 94 cm Men, 80 Women, less for South Asians

The smaller the waistline the better especially for those with
metabolic syndrome (MetS) which includes everyone with type-2 diabetes.

May GOD continue to heal our hearts with HIS living water so that we
can love others just a little bit more, dear brother Enrico whom I love
unconditionally.

Prayerfully in Christ's amazing love,

Andrew <><
--
Andrew B. Chung
Cardiologist, Atlanta, Georgia, USA
http://HeartMDPhD.com/HolySpirit

As for knowing who are the very elect, these you will know by the
unconditional love they have for everyone including their enemies
(Matthew 5:44-45, 1 Corinthians 13:3, James 2:14-17).
http://HeartMDPhD.com/Love


Enrico C wrote:
> 94cm = 37inches
> 80cm = 31/32inches
>
>
> What do you make of this...?
>
> http://www.ucdmc.ucdavis.edu/ome/mcr...definition.pdf
>
> The metabolic syndrome—a new worldwide definition
> [...]
> The International Diabetes Federation (IDF) felt there
> was a strong need for one practical definition that would
> be useful in any country for the identification of people at
> high risk of CVD, but also diabetes. This definition would
> also allow comparative long-term studies, which could
> then be used, if necessary, to refine the definition on the
> basis of solid endpoints. As a result, an IDF consensus
> group met in 2004, with representatives from the
> organisations that had generated the previous definitions
> and members from all IDF regions. Their recommenda-
> tions are now available.
> [...]
> Central obesity, as assessed by waist circumference, was
> agreed as essential (panel), because of the strength of the
> evidence linking waist circumference with cardiovascular
> disease and the other metabolic syndrome components,
> and the likelihood that central obesity is an early step in
> the aetiological cascade leading to full metabolic
> syndrome. The waist circumference cutoff selected was
> the same as that used by European Group for the Study of
> Insulin Resistance, and lower than the main Adult
> Treatment Panel III recommendations, because most
> available data suggest an increase in other cardiovascular
> disease risk factors in Europids (white people of European
> origin, regardless of where they live in the world) when
> the waist circumference rises above 94 cm in men and
> 80cm in women. Ethnic-specific waist circumference
> cutoffs have been incorporated into the definition (table),
> and have been based on available data linking waist
> circumference to other components of the metabolic
> syndrome in different populations. The levels of the
> other variables were as described by Adult Treatment
> Panel III, except that the most recent diagnostic level from
> the American Diabetes Association for impaired fasting
> glucose (5·6 mmol/L [100 mg/dL]) was used. Although
> this new definitionwill still miss substantial numbers of
> people with impaired glucose tolerance (because an oral
> glucose-tolerance test is not required), it retains the
> simplicity of the instrument.
> The consensus group also recommended additional
> criteria that should be part of further research into
> metabolic syndrome, including: tomographic assessment
> of visceral adiposity and liver fat, biomarkers of adipose
> tissue (adiponectin, leptin), apolipoprotein B, LDL particle
> size, formal measurement of insulin resistance and an oral
> glucose-tolerance test, endothelial dysfunction, urinary
> albumin, inflammatory markers (C-reactive protein,
> tumour necrosis factor , interleukin 6), and thrombotic
> markers (plasminogen activator inhibitor type 1,
> fibrinogen). These factors should be combined with
> assessment of CVD outcome and development of
> diabetes so better predictors can be developed.
> Researchers and clinicians should use the new criteria
> for the identification of high-risk individuals and for
> research studies. Preventive measures are obviously
> needed in the people identified. Mounting evidence
> suggests that lifestyle modification with weight loss and
> increased physical activity will be beneficial, although
> specific studies in metabolic syndrome are needed.
> [...]
>
>
> Panel:International Diabetes Federation: metabolic syndrome definition
>
> Central obesity
> Waist circumference*—ethnicity specific
>
> Table: Ethnic-specific values for waist circumference
> Ethnic group Waist circumference
> (as measure of central obesity)
> Europids* Men94 cm Women80 cm
> South Asians Men90 cm Women80 cm
> Chinese Men90 cm Women80 cm
> Japanese Men85 cm Women90 cm
> Ethnic south and central Americans Use south Asian recommendations until
> more specific data are available
> Sub-Saharan Africans Use European data until more specific data are
> available
> Eastern Mediterranean and middle east (Arab) populations Use European data
> until more specific data are available
> Data are pragmatic cutoffs and better data are required to link them to
> risk. Ethnicity should be basis for classification, not country of
> residence. *In USA, Adult Treatmen panel III values (102 cm male, 88 cm
> female) are likely to continue to be used for clinical purposes. In future
> epidemiological studies of populations of Europid origin (white people of
> European origin, regardless of where they live in the world),
> prevalence should be given, with both European and North American cutoffs
> to allow better comparisons.
>
>
>
>
> Plus any two:
>
> Raised triglycerides150 mg/dL (1·7 mmol/L)
> Specific treatment for this lipid abnormality
>
> Reduced HDL-cholesterol40 mg/dL (1·03 mmol/L) in men50 mg/dL (1·29 mmol/L)
> in women
> Specific treatment for this lipid abnormality
>
> Raised blood pressure
> Systolic 130 mm Hg
> Diastolic 85 mm Hg
> Treatment of previously diagnosed hypertension
>
> Raised fasting plasma glucoseâ€*
> Fasting plasma glucose 100 mg/dL (5·6 mmol/L)
> Previously diagnosed type 2 diabetes
> If above 5·6 mmol/L or 100 mg/dL, oral glucose tolerance test is strongly
> recommended, but is not necessary to define presence of syndrome
>
> *If body-mass index is over 30 kg/m , central obesity can be assumed and
> waist circumference does not need to be
> measured. â€*In clinical practice, impaired glucose tolerance is also
> acceptable, but all reports of prevalence of metabolic
> syndrome should use only fasting plasma glucose and presence of previously
> diagnosed diabetes to define hyperglycaemia. Prevalences also incorporating
> 2-h glucose results can be added as supplementary findings.
>
> [...]
>
> Lancet, Vol 366, September 24, 2005
>
>
>
> xpost sci.med.nutrition,sci.med.cardiology,misc.health.d iabetes

Convicted CoonSkin wrote:

http://HeartMDPhD.com/Convicts

> "The smaller the waistline the better especially for those with
> metabolic syndrome (MetS) which includes everyone with type-2 diabetes."
>
> Mostly valid

Completely valid.

Such is the nature of the truth, Whom I love with all my heart, soul,
mind, and strength:

http://HeartMDPhD.com/HolySpirit/fear.asp

Fear GOD and dread nothing that is of the world:

http://MabletonGA.OurLittle.net/DreadNought

Prepare the way for the LORD (Rejoice ! Atheism is dead ! ):

http://groups.google.com/group/sci.m...c99eb33ac3ec3?


Laus Deo ! !

Marana tha ! ! !

May GOD continue to heal our hearts with HIS living water so that we
can love others a little bit more, dear neighbor CoonSkin whom I love
unconditionally.

Prayerfully in Christ's amazing love,

Andrew <><
--
Andrew B. Chung
Cardiologist, Atlanta, Georgia, USA
http://HeartMDPhD.com/HolySpirit

As for knowing who are the very elect, these you will know by the
unconditional love they have for everyone including their enemies
(Matthew 5:44-45, 1 Corinthians 13:3, James 2:14-17).
http://HeartMDPhD.com/Love

False teacher CoonSkin (aka MWPhelps) wrote:
> Andrew, in the Holy Spirit, boldly wrote:
>
> > "The smaller the waistline the better especially for those with
> > metabolic syndrome (MetS) which includes everyone with type-2 diabetes."
>
> Mostly valid

You remain false:

http://groups.google.com/group/sci.m...c2d7e3d655a7e?

Atheist false teacher CoonSkin (aka MWPhelps, CapMack et al) wrote:
> Andrew, in the Holy Spirit, boldly wrote:
>
> > "The smaller the waistline the better especially for those with
> > metabolic syndrome (MetS) which includes everyone with type-2 diabetes."
>
> <CoonSkin's perseveration read, noted, and snipped>

Your difficulties simply show that you remain condemned:

http://groups.google.com/group/sci.m...c2d7e3d655a7e?

How's the job, Andy?

TC

Andrew B. Chung, MD/PhD wrote:
> The smaller the waistline the better especially for those with
> metabolic syndrome (MetS) which includes everyone with type-2 diabetes.
>
> May GOD continue to heal our hearts with HIS living water so that we
> can love others just a little bit more, dear brother Enrico whom I love
> unconditionally.
>
> Prayerfully in Christ's amazing love,
>
> Andrew <><
> --
> Andrew B. Chung
> Cardiologist, Atlanta, Georgia, USA
> http://HeartMDPhD.com/HolySpirit
>
> As for knowing who are the very elect, these you will know by the
> unconditional love they have for everyone including their enemies
> (Matthew 5:44-45, 1 Corinthians 13:3, James 2:14-17).
> http://HeartMDPhD.com/Love
>
>
> Enrico C wrote:
> > 94cm = 37inches
> > 80cm = 31/32inches
> >
> >
> > What do you make of this...?
> >
> > http://www.ucdmc.ucdavis.edu/ome/mcr...definition.pdf
> >
> > The metabolic syndrome—a new worldwide definition
> > [...]
> > The International Diabetes Federation (IDF) felt there
> > was a strong need for one practical definition that would
> > be useful in any country for the identification of people at
> > high risk of CVD, but also diabetes. This definition would
> > also allow comparative long-term studies, which could
> > then be used, if necessary, to refine the definition on the
> > basis of solid endpoints. As a result, an IDF consensus
> > group met in 2004, with representatives from the
> > organisations that had generated the previous definitions
> > and members from all IDF regions. Their recommenda-
> > tions are now available.
> > [...]
> > Central obesity, as assessed by waist circumference, was
> > agreed as essential (panel), because of the strength of the
> > evidence linking waist circumference with cardiovascular
> > disease and the other metabolic syndrome components,
> > and the likelihood that central obesity is an early step in
> > the aetiological cascade leading to full metabolic
> > syndrome. The waist circumference cutoff selected was
> > the same as that used by European Group for the Study of
> > Insulin Resistance, and lower than the main Adult
> > Treatment Panel III recommendations, because most
> > available data suggest an increase in other cardiovascular
> > disease risk factors in Europids (white people of European
> > origin, regardless of where they live in the world) when
> > the waist circumference rises above 94 cm in men and
> > 80cm in women. Ethnic-specific waist circumference
> > cutoffs have been incorporated into the definition (table),
> > and have been based on available data linking waist
> > circumference to other components of the metabolic
> > syndrome in different populations. The levels of the
> > other variables were as described by Adult Treatment
> > Panel III, except that the most recent diagnostic level from
> > the American Diabetes Association for impaired fasting
> > glucose (5·6 mmol/L [100 mg/dL]) was used. Although
> > this new definitionwill still miss substantial numbers of
> > people with impaired glucose tolerance (because an oral
> > glucose-tolerance test is not required), it retains the
> > simplicity of the instrument.
> > The consensus group also recommended additional
> > criteria that should be part of further research into
> > metabolic syndrome, including: tomographic assessment
> > of visceral adiposity and liver fat, biomarkers of adipose
> > tissue (adiponectin, leptin), apolipoprotein B, LDL particle
> > size, formal measurement of insulin resistance and an oral
> > glucose-tolerance test, endothelial dysfunction, urinary
> > albumin, inflammatory markers (C-reactive protein,
> > tumour necrosis factor , interleukin 6), and thrombotic
> > markers (plasminogen activator inhibitor type 1,
> > fibrinogen). These factors should be combined with
> > assessment of CVD outcome and development of
> > diabetes so better predictors can be developed.
> > Researchers and clinicians should use the new criteria
> > for the identification of high-risk individuals and for
> > research studies. Preventive measures are obviously
> > needed in the people identified. Mounting evidence
> > suggests that lifestyle modification with weight loss and
> > increased physical activity will be beneficial, although
> > specific studies in metabolic syndrome are needed.
> > [...]
> >
> >
> > Panel:International Diabetes Federation: metabolic syndrome definition
> >
> > Central obesity
> > Waist circumference*—ethnicity specific
> >
> > Table: Ethnic-specific values for waist circumference
> > Ethnic group Waist circumference
> > (as measure of central obesity)
> > Europids* Men94 cm Women80 cm
> > South Asians Men90 cm Women80 cm
> > Chinese Men90 cm Women80 cm
> > Japanese Men85 cm Women90 cm
> > Ethnic south and central Americans Use south Asian recommendations until
> > more specific data are available
> > Sub-Saharan Africans Use European data until more specific data are
> > available
> > Eastern Mediterranean and middle east (Arab) populations Use European data
> > until more specific data are available
> > Data are pragmatic cutoffs and better data are required to link them to
> > risk. Ethnicity should be basis for classification, not country of
> > residence. *In USA, Adult Treatmen panel III values (102 cm male, 88 cm
> > female) are likely to continue to be used for clinical purposes. In future
> > epidemiological studies of populations of Europid origin (white people of
> > European origin, regardless of where they live in the world),
> > prevalence should be given, with both European and North American cutoffs
> > to allow better comparisons.
> >
> >
> >
> >
> > Plus any two:
> >
> > Raised triglycerides150 mg/dL (1·7 mmol/L)
> > Specific treatment for this lipid abnormality
> >
> > Reduced HDL-cholesterol40 mg/dL (1·03 mmol/L) in men50 mg/dL (1·29 mmol/L)
> > in women
> > Specific treatment for this lipid abnormality
> >
> > Raised blood pressure
> > Systolic 130 mm Hg
> > Diastolic 85 mm Hg
> > Treatment of previously diagnosed hypertension
> >
> > Raised fasting plasma glucoseâ€*
> > Fasting plasma glucose 100 mg/dL (5·6 mmol/L)
> > Previously diagnosed type 2 diabetes
> > If above 5·6 mmol/L or 100 mg/dL, oral glucose tolerance test is strongly
> > recommended, but is not necessary to define presence of syndrome
> >
> > *If body-mass index is over 30 kg/m , central obesity can be assumed and
> > waist circumference does not need to be
> > measured. â€*In clinical practice, impaired glucose tolerance is also
> > acceptable, but all reports of prevalence of metabolic
> > syndrome should use only fasting plasma glucose and presence of previously
> > diagnosed diabetes to define hyperglycaemia. Prevalences also incorporating
> > 2-h glucose results can be added as supplementary findings.
> >
> > [...]
> >
> > Lancet, Vol 366, September 24, 2005
> >
> >
> >
> > xpost sci.med.nutrition,sci.med.cardiology,misc.health.d iabetes

On 5 Dec 2006 09:33:24 -0800, tunderbar@hotmail.com wrote:

>How's the job, Andy?

Would you at least quit quoting the quack when you respond to his
bait? Some of us have him killfiled...

WoolyGooly wrote:
> On 5 Dec 2006 09:33:24 -0800, tunderbar@hotmail.com wrote:
>
> >How's the job, Andy?
>
> Would you at least quit quoting the quack when you respond to his
> bait? Some of us have him killfiled...

sorry